634 results about "Effector" patented technology

The invention belongs to the field of prevention and treatment of tilletia controversa Kuhn, and particularly relates to a tilletia controversa Kuhn effect protein g16561 and application thereof. An amino acid sequence of the Tilletia controversa Kuhn effect protein is shown as SEQ ID NO: 2. The effect protein plays an important role in the process of inhibiting plant defense reaction, and has an interaction relationship with a wheat protein in the process of infecting wheat by Tilletia controversa Kuhn. According to the invention, the pathogenesis of Tilletia controversa Kuhn can be deeply researched, and the excavation of wheat disease-resistant genes and the cultivation of wheat disease-resistant varieties can be promoted.

The present disclosure relates to compositions and methods for reducing expression of MYC gene in a cell. In some embodiments, an expression repressor comprises a targeting moiety that binds a MYC promoter, anchor sequence, or super-enhancer. In some embodiments, the expression repressor comprises an effector moiety that represses transcription or methylates DNA. Systems comprising two expression repressors are also disclosed. The compositions can be used, for example, to treat cancers such as HCC.

The invention relates to a ligand-effector moiety provided with at least one saponin and antibody-effector moiety provided with at least one saponin. An aspect of the invention is a composition comprising the ligand-effector moiety provided with at least one saponin or the antibody-effector moiety provided with at least one saponin of the invention. The invention also relates to an antibody-drug conjugate comprising covalently linked saponin and to an antibody-oligonucleotide conjugate comprising covalently linked saponin. An aspect of the invention relates to a pharmaceutical composition comprising the ligand-effector moiety provided with at least one saponin or the antibody-effector moiety provided with at least one saponin of the invention, and optionally further comprising a pharmaceutically acceptable excipient. The invention also relates to the ligand-effector moiety provided with at least one saponin or the antibody-effector moiety provided with at least one saponin, for use as a medicament. The invention also relates to the ligand-effector moiety provided with at least one saponin or the antibody-effector moiety provided with at least one saponin of the invention for use in the treatment or prophylaxis of a cancer.

The disclosure provides, for example, double stranded DNA (dsDNA) molecules comprising one or more chemically modified nucleobases. In some embodiments, the dsDNA molecule is circular and comprises a first strand and a second strand, wherein the first strand comprises one or more chemically modified nucleobases, and the second strand is free of chemically modified nucleobases. In some embodiments, the dsDNA molecule comprises a promoter sequence and an effector sequence that encodes an effector.

The invention belongs to the technical field of immunotherapy, and particularly relates to a method for improving NK cell functions by targeted inhibition of lactylation. The invention provides a method for improving functions of NK cells by targeted inhibition of lactylation, NK cell lactic acid transporters or modification enzymes in inhibition of the lactylation process are targeted, the modification enzymes are NK cell lactylation modification enzymes Writer or lactic acid coenzyme A synthetase, NK92MI lactylation modification is blocked, so that function depletion of the NK cells is reversed, and the NK cell function is improved. The function of the NK cell can be partially reversed by inhibiting the lactic acid modification, and the expression level of effector molecules of the NK92MI cell can be recovered.

The invention discloses an arabidopsis thaliana RK3 gene and application of S structural domain receptor kinase RK3 coded by the arabidopsis thaliana RK3 gene in improvement of plant disease resistance, and belongs to the technical field of plant genetic engineering. According to the application of the arabidopsis thaliana RK3 gene to improvement of plant disease resistance, the nucleotide sequence of the arabidopsis thaliana RK3 gene is shown as SEQ ID NO.1, the amino acid sequence of S structural domain receptor kinase RK3 coded by the arabidopsis thaliana RK3 gene is shown as SEQ ID NO.2, and further plants are selected from arabidopsis thaliana, oilseed rape, rice, tomatoes, potatoes, peanuts, soybeans, cotton, tobacco, cucumbers, watermelons and the like. The expression of the plant disease resistance comprises infection resistance to wild-type pseudomonas syringae, effector engineering strains thereof and botrytis cinerea. It is clear that the arabidopsis thaliana RK3 gene and the encoded protein thereof can remarkably enhance the infection resistance of plants to various pathogenic bacteria for the first time, disease prevention and control are achieved by activating the autoimmune system of the plants, and an effective path is provided for reducing chemical pesticide application and promoting agricultural green development.

The present disclosure provides one or more engineered gene effectors and systems, compositions, and methods of use thereof, wherein the one or more engineered gene effectors can be used to effect regulation of a target gene in a cell (e.g., an endogenous target gene in a cell). The one or more engineered gene effectors can be operatively coupled to a heterologous endonuclease, such as a CRISPR / Cas protein.

The invention discloses an effect protein E56, a coding gene and application of the effect protein E56 to improvement of southern rust resistance of corn, and belongs to the technical field of agricultural biology. The amino acid sequence of the effector protein E56 is as shown in SEQ ID NO. 1. A reverse genetics method is utilized to analyze the Puccinia polystachys effect protein E56 gene, and the E56 gene is up-regulated in expression in the Puccinia polystachys infection process. The E56 gene is silenced by adopting a host-mediated gene silencing technology, and the toxic function of the E56 gene in the infection process of the southern rust disease is determined. A specific fragment of the E56 gene is cloned to an RNAi interference vector, a corn immature embryo is transformed by using an agrobacterium tumefaciens-mediated transgenic technology, and an obtained transgenic corn plant shows resistance to the corn southern rust disease. The E56-RNAi transgenic plant shows resistance to puccinia polypoda, so that the effect protein E56 can be used for creating a new strain for resisting the southern rust disease.

The invention relates to the field of nucleic acid editing, in particular to the technical field of regularly clustered interval short palindromic repeat (CRISPR). In particular, the invention relates to a mutant of a Cas effector protein, a fusion protein comprising the mutant, and nucleic acid molecules encoding the same. The invention also relates to complexes and compositions for nucleic acid editing (e.g., gene or genome editing). The invention also relates to methods for nucleic acid editing (e.g., gene or genome editing) using the proteins or fusion proteins comprising the invention. Compared with a wild type Cas protein, the Cas protein mutant disclosed by the invention has better activity, such as higher cleavage activity, stronger target site recognition capability and higher target sequence editing activity.

The invention relates to the technical field of antitumor drugs, in particular to a Ru (II) complex and a preparation method and application thereof, and the Ru (II) complex has a structure as shown in a formula I. The Ru (II) complex synthesized by the method disclosed by the invention not only has relatively high cytotoxicity, but also has good photodynamic antitumor activity. After the complex is illuminated, the efficiency of the complex entering cells in an active transportation mode can be accelerated, mitochondria and endoplasmic reticulum are targeted at the same time, mitochondrial membrane potential decline and endoplasmic reticulum stress are caused to form a dual organelle damage effect, immunogenic cell death is caused, the tumor microenvironment is adjusted, and the tumor cell immunogenicity is improved. The enrichment of dendritic cells (DCs) in tumor cells is realized, the chemotactic activity of effector T cells is improved, the proportion of CD4 < + > and Foxp3 < + > cell populations is reduced, and finally the anti-tumor immune response is activated. Meanwhile, the complex provided by the invention can also induce the cell to generate pan apoptosis, retard the cell cycle in the G2 / M period and enhance the effect of the complex in inhibiting tumor proliferation.

The invention relates to tilletia foetida, in particular to a tilletia foetida effect protein TlRlpA and application thereof. The invention provides a Tilletia foetida effect protein, and the amino acid sequence of the Tilletia foetida effect protein is shown as SEQ ID NO: 2, SEQ ID NO: 4 or SEQ ID NO: 6. The effector protein can effectively inhibit programmed death of plant cells induced by BAX, and plays an important role in inhibiting a plant defense reaction process. The invention lays a foundation for deeply researching the pathogenesis of the tilletia foetida, excavating the tilletia foetida-resistant gene of the wheat and developing the tilletia foetida-resistant wheat variety.

The disclosure provides, for example, DNA molecules comprising at least one nucleotide with a macromolecule, small molecule, or reactive handle (e.g., click handle) appended to a phosphorothioate backbone. The disclosure also provides methods for making such DNA molecules, for example using click chemistry. In some embodiments, the DNA molecule comprises a sequence that encodes an effector (e.g., a therapeutic effector).

Antibodies, antigen-binding proteins and Fc-fusion proteins that comprise recombinant polypeptides containing a chimeric heavy chain constant region sequence are provided that bind to certain Fc receptors however have reduced effector functions. Methods of making constructs for expression of such chimeric Fc-containing antibodies, antigen-binding proteins and Fc-fusion proteins in cell systems, and methods of producing and isolating the chimeric Fc-containing proteins are provided.

The invention relates to the field of nucleic acid editing, in particular to the technical field of regularly clustered interval short palindromic repeat (CRISPR). In particular, the invention relates to a mutant of a Cas effector protein, a fusion protein comprising the mutant, and nucleic acid molecules encoding the same. The invention also relates to complexes and compositions for nucleic acid editing (e.g., gene or genome editing). The invention also relates to methods for nucleic acid editing (e.g., gene or genome editing) using the proteins or fusion proteins comprising the invention. Compared with a wild type Cas protein, the Cas protein mutant disclosed by the invention has better activity, such as higher cleavage activity, stronger target site recognition capability and higher target sequence editing activity.

The disclosure provides, for example, a DNA molecule comprising a first strand of DNA, wherein the first strand is circular and single stranded over at least 90% of its length, and a second strand of DNA covalently linked to the first strand as described herein. The DNA molecule may comprise an effector sequence encoding a therapeutic effector. In some embodiments, the DNA molecule shows improved conversion to double-stranded DNA relative to a DNA molecule that lacks the second strand.

The disclosure provides, for example, double stranded DNA (dsDNA) molecules comprising one or more chemically modified nucleobases. In some embodiments, the dsDNA molecule is circular and comprises a first strand and a second strand, wherein the first strand comprises one or more chemically modified nucleobases, and the second strand is free of chemically modified nucleobases. In some embodiments, the dsDNA molecule comprises a promoter sequence and an effector sequence that encodes an effector.

The present disclosure relates to enzymes, compositions and methods for performing conditional homologous recombination of a targeted DNA molecule or genome by using modified proteins comprising nucleic acid DNA binding proteins with protease-conditional recombinase (hereinafter “ProRec”) activity. Namely a new cre recombinase pro enzyme, compositions / kit and sensors comprising the cre recombinase pro enzyme of the present disclosure. Namely, a cre recombinase pro-enzyme, for identifying and quantifying proteolytic activity in a disease or an infection, comprising intein mediated circularization, a flip-excision cassette comprising an output reporter and / or effector protein; a linker sequence cleavable by a protease.

An iRGD-LAMP2B-EGFP fusion protein mediated exosome surface engineering strategy is adopted, through specific recognition of iRGD peptide and integrin alpha v beta 3, corneal neovascularization core lesion cells are actively targeted, the limitation of off-target toxicity of a traditional delivery system is broken through, and a'accurate focus recognition-efficient homing 'targeted delivery normal form is established. Meanwhile, the screened circular RNA with anti-inflammatory and anti-angiogenesis dual activities is used as a core effector molecule, and in combination with an in-situ loading technology of the circular RNA molecule in an exosome parent cell, stable entrapment and targeted release of a nucleic acid drug in an exosome cavity are realized, and the problems that the nucleic acid drug is easy to degrade and poor in targeting property are solved; and dual guarantee of function specificity and delivery stability is formed. And a synergistic treatment system of a targeting exosome carrier and bifunctional circular RNA is further constructed, active molecules are accurately delivered to focus cells, and an inflammation microenvironment and an angiogenesis pathway are synchronously regulated and controlled.

The invention provides an application of a reagent for detecting an effector CD4 + T cell in peripheral blood of a subject in preparation of a product for diagnosing membranous nephropathy, lupus nephritis or ANCA-related vasculitis. The invention also provides an application of the effector CD4 + T cell in peripheral blood in preparation of a diagnostic model for diagnosing membranous nephropathy, lupus nephritis or ANCA-related vasculitis. The marker is detected through flow cytometry, and the result shows that the Ejector CD4 + T cell is remarkably increased in a patient with membranous nephropathy, can effectively distinguish membranous nephropathy from healthy control (verification set AUC 0.8098), can assist in identifying membranous nephropathy, lupus nephritis (verification set AUC 0.8686) and ANCA-related vasculitis (verification set AUC 0.8968), and the level of the Ejector CD4 + T cell is related to whether membranous nephropathy is difficult to treat or not.

The invention discloses a tool for realizing efficient specific gene inhibition in a plant by utilizing a SunTag system of CRISPR-dCas9 (clustered regularly interspaced short palindromic repeats-das9). According to the method, gRNA near a transcription start site of a targeted target gene is designed, dCas9 and scFv-GFP are accurately recruited to a target site by using a SunTag system, the transcription start process of RNA polymerase II is interfered, and the expression of the target gene is remarkably inhibited. In view of relatively high activity of the system in a plant rdr6 mutant, an artificial miR-RDR6 fragment is further introduced into a vector and is used for inhibiting expression of RDR6 in a wild plant, so that the applicability and functionality of the system are expanded. Compared with a traditional method depending on a plant endogenous effector, the method has the advantages that dependence on endogenous regulatory factors is avoided, the specificity and safety of gene inhibition are remarkably improved, and the method can be used for plant genetic function research and character improvement.

The invention discloses an IV-type secretory effect protein recognition method and system based on multi-modal information, and belongs to the technical field of bioinformatics and secretory protein recognition. The method comprises the following steps: firstly, extracting amino acid residue characteristics of protein by using a protein language model, and constructing a spatial adjacency graph of the protein by using a three-dimensional structure predicted by a protein structure prediction model; respectively extracting sequence features and structural features of the protein through a deep sequence module and a hierarchical graph module; meanwhile, a contrast learning module is introduced to realize cross-modal alignment of the same protein in a potential space; and performing bidirectional interaction on the sequence features and the structural features by using a cross attention module to obtain joint features, and finally outputting a classification result after nonlinear transformation by a gating linear unit for predicting the IV-type secretion effect protein. According to the invention, efficient coordination of sequence and structure bimodal information is realized, and the identification accuracy of the IV-type secretory effect protein is remarkably improved.

The present invention generally relates to tRNA-based effector molecules for use in inserting missense mutations into the open reading frame (ORF) of a gene, e.g., for the treatment of repetitive sequence amplification diseases.

Provided herein are compositions, systems, and methods for the creation, identification, and characterization of effector domains for activating and silencing gene expression. In particular, a high-throughput system for discovering and characterizing effector domains is provided.

The invention discloses a diaphorina citri effector protein DcPDI1 and an application thereof. The amino acid sequence of the diaphorina citri effector protein DcPDI1 is as shown in SEQ ID NO. 1, and the nucleotide sequence of the diaphorina citri effector protein DcPDI1 is as shown in SEQ ID NO. 2. After the diaphorina citri DcPDI1 is knocked out, the egg laying amount and the developmental duration of the diaphorina citri are remarkably reduced, and it is indicated that the DcPDI1 plays an important role in growth and development of the diaphorina citri. The diaphorina citri effect protein DcPDI1 can be a new molecular target spot, plays a key role in activating defensive response of host plants and helping diaphorina citri to eat, and provides a new insight for a molecular mechanism of interaction between diaphorina citri and plants.

Compositions are provided for transient transcriptional modulation of genes through delivery of RNA molecules encoding site-specific DNA binding molecules linked to transcriptional modulation domains, as well as methods for treating or preventing a disease or disorder, including a cancer, infectious disease, or immunological disease.

A polypeptide linker (2 to 21 amino acids) is connected to a carrier peptide based on the Ioop2 domain of lynx1. The carrier or transporter peptide may be further coupled via the polypeptide linker to a molecule of interest (MOI) or effector agent, such as a protein or protein domain or any other biomolecule (e.g., biomolecules having a molecular weight of 10kDa to 230 kDa). In some embodiments, the complex may be used therapeutically in targeting various neurological disease-causing cellular components.

To provide a method for determining the presence or absence of a target nucleic acid molecule in a sample.SOLUTION: CLAIMS What is claimed is: 1. A method of amplifying a target nucleic acid molecule in a sample, comprising: a) an effector complex comprising a Type III CRISPR-associated effector protein (Cas) and at least one CRISPRRNA (crRNA) that binds to the target nucleic acid molecule; and b) means for directly or indirectly determining the level of cyclic oligoadenylate (cOA). Providing a sample with a Regularly Interspaced Short Palindromic Repeats (CRISPR) - based ribonucleic acid detection system; incubating the sample under conditions that allow the crRNA to bind to its target nucleic acid molecule; and directly or indirectly determining the level of cyclic oligoadenylate (cOA), wherein an increase in the determined cOA level relative to a control is indicative of the presence of the target molecule in the sample.SELECTED DRAWING: None

The present disclosure is directed to compositions and methods for increasing expression of target genes in a cell, e.g., using an expression activator that comprises a targeting moiety that binds a target gene and an effector domain comprising an epigenetic activating domain. Systems comprising two or more expression activators are also disclosed.

Novel anti-effector moiety antibodies or antigen binding domains thereof and CARs that contain such effector moiety antigen binding domains, either with or without one or more booster elements, and host cells expressing the receptors, and nucleic acid molecules encoding the receptors are provided herein, as well as methods of use of same in a patient-specific immunotherapy that can be used to treat solid tumor cancers and other diseases and conditions.

The invention relates to a method for controlling a sensor-effector system (10), in which a trajectory (12) of a target (14) to be attacked is predicted. Furthermore, at least one section of a first type of the predicted trajectory (12) is determined, which section is located within the range of an effector (16) of the sensor-effector system (10). A hit probability of the effector (16) is determined for different points along the at least one section of the first type. In addition, at least one section of a second type of the predicted trajectory (12) is determined (112), which section overlaps with a field of view of a sensor (18) of the sensor-effector system (10). With regard to the sensor (18), a quality of visibility at different points of the at least one section of the second type is then determined. Along a region of the predicted trajectory (12) in which the section of the first type and the at least one section of the second type of the predicted trajectory (12) overlap, a combat point (20) is then selected on the basis of the determined hit probability and on the basis of the determined quality of visibility.